Our Thesis

The most durable value in molecular diagnostics is created at the tools and consumables layer — recurring, high‑margin reagent revenue tied to growing testing volumes across clinical and research settings.

We believe the best opportunities in this space share a few characteristics:

· Proven demand and demonstrated commercial traction, not speculative market creation.

· Technologies or product lines that are strong at the product level but constrained by capital, structure, or operating capacity.

· Clear paths to recurring revenue through consumable kit models — not one‑time service engagements.

· IP positions that protect the core product franchise and open licensing or partnership optionality.

The Venture Studio Advantage

Traditional venture capital funds companies from the outside. Venture studios build from the inside. At G3, our operating team is embedded in each portfolio company — running finance, quality, manufacturing, and commercial execution directly.

This model gives us a structural advantage in identifying, acquiring, and scaling molecular tools businesses that are too operationally intensive for passive investors but not yet large enough for strategic acquirers.

Where We Are Headed

G3 is building toward a focused portfolio of three to four operating companies in molecular diagnostics and genomics tools, connected by shared infrastructure and a common operating playbook. Our near‑term priorities are scaling Bandit Bio's SeqOnce™ product revenue, advancing CrestForge's novel platform to commercial readiness, and expanding CrestForge's CMO client base.